Bank of America Securities analyst Travis Steed has maintained their bullish stance on CBLL stock, giving a Buy rating on April 4.
Travis Steed has given his Buy rating due to a combination of factors, including Ceribell, Inc.’s improved gross margin projections despite the impact of tariffs. The company’s post-tariff gross margin is now estimated at 71%, which is an improvement from the previous estimate of 68%. This increase is significant considering the substantial tariffs imposed on materials sourced from China, which play a crucial role in Ceribell’s manufacturing process.
Furthermore, Ceribell’s strategic use of contract manufacturers in China allows them to avoid transfer pricing issues, contributing to their favorable financial outlook. The company’s stock is currently priced at 19.23 USD, with a price objective set at 32.00 USD, indicating potential upside. These factors, combined with Ceribell’s ability to manage tariff impacts effectively, support Travis Steed’s Buy rating for the stock.
Steed covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Abbott Laboratories, and Dexcom. According to TipRanks, Steed has an average return of 4.4% and a 51.71% success rate on recommended stocks.
In another report released on April 4, Ladenburg Thalmann & Co. also initiated coverage with a Buy rating on the stock with a $32.00 price target.